Iceu Dimas Kulsum, Faisal Yunus
Departemen Pulmonologi dan Kedokteran Respirasi, Fakultas Kedokteran Universitas Indonesia, RSUP Persahabatan, Jakarta
Abstract
Metabolic syndrome is a complex disorder and an emerging clinical challenge, recognized clinically by the findings of abdominal obesity, elevated triglycerides, atherogenic dyslipidemia, elevated blood pressure, high blood glucose and/or insulin resistance. Metabolic syndrome is 1.5-3 times more common in COPD than in the general population. This association is accounted for by common risk factors, such as smoking, physical inactivity, obesity, systemic inflammation and corticosteroid treatment, all of which increase insulin resistance. COPD patients with metabolic syndrome have increased systemic inflammation, which may contribute to increased mortality, more frequent and prolonged respiratory exacerbation and hospitalization. Modification of standard exercise programs, nutritional advice, pharmacotherapy for insulin resistance and management of all others comorbidities have potential to improve COPD outcomes and decrease risk for cardiovascular event and others metabolic diseases. (J Respir Indo. 2016; 36: 47-59)
Keywords: Metabolic syndrome, COPD, comorbidity.